Drugs Containing Excipient (Inactive Ingredient) BENZYL BENZOATE

Branded drugs containing BENZYL BENZOATE excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AstraZeneca Pharmaceuticals LP	FASLODEX	fulvestrant	0310-0720	BENZYL BENZOATE
Akorn	BAL	dimercaprol	17478-526	BENZYL BENZOATE
Azurity Pharmaceuticals Inc	AZMIRO	testosterone cypionate	24338-056	BENZYL BENZOATE
AMAG Pharmaceuticals Inc	MAKENA	hydroxyprogesterone caproate	64011-243	BENZYL BENZOATE
Endo USA Inc	AVEED	testosterone undecanoate	67979-511	BENZYL BENZOATE	2027-03-14

Generic drugs containing BENZYL BENZOATE excipient

Company	Ingredient	NDC	Excipient
Pharmacia & Upjohn Company LLC	testosterone cypionate	0009-0085	BENZYL BENZOATE
Pharmacia & Upjohn Company LLC	testosterone cypionate	0009-0347	BENZYL BENZOATE
Hikma Pharmaceuticals USA Inc	testosterone cypionate	0143-9005	BENZYL BENZOATE
Hikma Pharmaceuticals USA Inc	fulvestrant	0143-9022	BENZYL BENZOATE
Hikma Pharmaceuticals USA Inc	estradiol valerate	0143-9290	BENZYL BENZOATE

Benzyl Benzoate Excipient Market Dynamics, Supply Chain, Regulation, and Financial Trajectory

Last updated: August 12, 2026

Benzyl benzoate is a mature, low-cost pharmaceutical excipient and specialty chemical with demand tied to topical medicines, injectable and depot formulations, cosmetics, fragrances, and veterinary products. Its commercial profile is volume-driven rather than patent-driven. The molecule has no meaningful remaining composition-of-matter exclusivity, and competition is based on specification control, manufacturing economics, regulatory documentation, supply reliability, and geographic reach.

The financial outlook is stable to moderately positive. Growth depends on pharmaceutical formulation demand, regulated-market quality upgrades, and expansion in emerging markets. Pricing power is limited because multiple manufacturers can produce the compound and pharmaceutical customers can qualify alternative suppliers.

What is benzyl benzoate and how is it used in pharmaceuticals?

Benzyl benzoate is the benzoic acid ester of benzyl alcohol, with CAS Registry Number 120-51-4 and molecular formula C14H12O2. It is a clear, oily liquid with low water solubility and useful solvency characteristics. The compound is produced mainly by esterification or transesterification routes involving benzoic acid, benzyl alcohol, or related intermediates.

In pharmaceutical products, benzyl benzoate can function as:

• A solvent or co-solvent for poorly water-soluble active ingredients.
• A vehicle in topical and dermatological formulations.
• A formulation component in depot or sustained-release products.
• A fragrance or processing component in products where the regulatory pathway permits its use.
• An active ingredient in certain scabies and lice treatments outside the United States or in nonstandardized markets.

The excipient and active-pharmaceutical-ingredient markets should be analyzed separately. Pharmaceutical-grade benzyl benzoate sold as an excipient competes on compendial compliance and documentation. Benzyl benzoate sold in a scabicide product competes on clinical labeling, dosage form, market authorization, and therapeutic positioning.

How large is the benzyl benzoate pharmaceutical excipient market?

No authoritative public dataset reports a standalone global market value for pharmaceutical-grade benzyl benzoate. Commercial market reports usually combine pharmaceutical, cosmetics, personal care, fragrance, and industrial grades. Those categories have different pricing, quality requirements, and growth rates.

The pharmaceutical excipient segment is a minority of total benzyl benzoate consumption but has higher quality-adjusted value. Its demand is driven by:

1. Topical dermatology products.
2. Injectable and depot formulations that require hydrophobic solvents.
3. Contract manufacturing and reformulation activity.
4. Growth in generic and multisource medicines.
5. Regional demand for scabies and parasitic-disease treatments.
6. Supplier qualification in regulated markets.

The underlying market is mature. Volume growth is likely to track low-single-digit pharmaceutical demand in established markets, with higher growth possible in India, Southeast Asia, Latin America, the Middle East, and Africa. Revenue growth can exceed volume growth when customers shift from technical or cosmetic grade to pharmaceutical-grade material requiring stronger documentation and tighter impurity controls.

Pharmaceutical versus nonpharmaceutical demand

Segment	Main use	Quality sensitivity	Pricing profile	Growth outlook
Pharmaceutical excipient	Solvent, vehicle, formulation aid	High	Medium	Stable to moderate
Dermatology active	Scabies and lice products	High	Medium to high	Regionally variable
Cosmetics and personal care	Fragrance, emollient, solvent	Medium	Low to medium	Moderate
Fragrance industry	Fixative and odor profile	Medium	Low to medium	Stable
Industrial	Solvent and processing use	Low to medium	Low	Low
Veterinary	Antiparasitic and formulation use	Medium	Medium	Moderate

What drives benzyl benzoate demand?

Demand is linked to formulation utility rather than therapeutic innovation. The main commercial drivers are the following.

Topical and dermatology formulations

Benzyl benzoate has a long history in topical antiparasitic products, particularly scabies treatments. It is also used as a vehicle or solvent in selected topical formulations. Demand is strongest where low-cost topical treatment is preferred and where local regulatory systems permit benzyl benzoate-containing products.

The product’s low raw-material cost supports generic and locally manufactured formulations. That limits margin expansion but supports recurring volume.

Injectable and depot formulations

Benzyl benzoate can be used as a hydrophobic solvent or vehicle in selected injectable and long-acting formulations. This segment is technically more demanding because manufacturers must control residual solvents, water content, particulate matter, sterility-related risks, extractables, leachables, and compatibility with container-closure systems.

A supplier qualified for an injectable application can have greater customer retention than a supplier serving fragrance or industrial buyers. The qualification cycle is longer, and switching requires formulation, stability, and regulatory review.

Generic drug manufacturing

Generic-drug manufacturers use established excipients to reproduce reference-product performance or develop alternative formulations. Benzyl benzoate is attractive when it provides solvency, viscosity, or vehicle properties at a lower cost than more specialized excipients.

Generic competition also creates price pressure. Large buyers can qualify multiple sources and negotiate based on annual volume, delivery reliability, and analytical documentation.

Cosmetics and fragrance

Cosmetics and fragrances provide a large adjacent market. These applications can absorb material that does not meet the highest pharmaceutical documentation requirements, but they also compete for manufacturing capacity and raw materials. A producer with a broad customer base can optimize plant utilization across pharmaceutical, cosmetic, and industrial grades.

What is the FDA regulatory status of benzyl benzoate?

Benzyl benzoate is not a novel pharmaceutical active ingredient. Its regulatory status depends on the product, route of administration, intended function, concentration, and jurisdiction.

The FDA Inactive Ingredient Database is the relevant starting point for evaluating prior use in approved drug products. Inclusion in the database does not constitute blanket approval for every route, dose, concentration, or formulation. Sponsors must assess the specific inactive-ingredient precedent and demonstrate suitability in the proposed product. [1]

For a pharmaceutical excipient, the principal regulatory questions are:

• Is the material used in an FDA-approved product by the intended route?
• Does the proposed concentration fall within an established precedent?
• Does the supplier meet the relevant compendial and quality specifications?
• Are impurities, residual solvents, elemental impurities, and degradation products controlled?
• Is the material suitable for the proposed container and formulation?
• Does the product require a new drug application, abbreviated new drug application, biologics license application, or another pathway?

In Europe, the excipient assessment is conducted within the medicinal-product authorization framework. Sponsors must provide appropriate quality information and justify excipient safety and function. European regulatory expectations also place emphasis on excipient risk assessment, supplier controls, and manufacturing consistency. [2]

Does benzyl benzoate have a USP-NF or Ph. Eur. monograph?

Benzyl benzoate has longstanding pharmaceutical and chemical standardization. Pharmacopeial status should be checked against the current edition and the specific market.

A compendial monograph typically addresses identity, assay, related substances, acidity or alkalinity, water, refractive index, density, and other quality attributes relevant to the material. The exact test set and acceptance criteria can differ by pharmacopeia and edition.

For procurement, the relevant distinction is between:

• Pharmaceutical grade with a current compendial certificate.
• GMP-manufactured material supported by a complete quality package.
• Cosmetic grade.
• Technical or industrial grade.

A certificate of analysis alone does not establish full pharmaceutical suitability. Buyers commonly evaluate the supplier’s GMP status, change-control system, audit history, impurity profile, traceability, data integrity, and ability to support regulatory filings.

The United States Pharmacopeia identifies benzyl benzoate in its compendial standards system, while European and other national pharmacopeias may apply their own monograph or general quality requirements. [3]

What patents protect benzyl benzoate?

The benzyl benzoate molecule is old and unpatentable as a new chemical entity in current commercial practice. Composition-of-matter patent protection has long expired. There is no commercially relevant basic patent estate that blocks production of benzyl benzoate as a chemical.

Potentially relevant intellectual property can still arise from:

• Specific topical compositions.
• Combination products.
• Novel delivery systems.
• Controlled-release or depot formulations.
• Manufacturing processes with improved purity or yield.
• Polymers, emulsions, nanoparticles, or other delivery vehicles containing benzyl benzoate.
• Brand-specific methods of treatment.

These rights protect a formulation, process, or therapeutic use, not the ordinary manufacture and sale of the excipient itself.

Patent and exclusivity profile

IP category	Relevance to benzyl benzoate	Commercial impact
Composition-of-matter patent	Expired or unavailable for the old molecule	None
Excipient-use patent	Uncommon	Low
Formulation patent	Possible	Product-specific
Manufacturing-process patent	Possible	Limited unless process is difficult to design around
Method-of-use patent	Possible for therapeutic products	Applies to labeled use, not general chemical supply
Regulatory exclusivity	Product-specific	No standalone excipient exclusivity
Trade secret	Possible for process optimization	Supplier-specific

When does benzyl benzoate lose exclusivity?

Benzyl benzoate has already lost any practical molecule-level exclusivity. The material is available from multiple chemical manufacturers and distributors. No Orange Book exclusivity period applies to benzyl benzoate as an excipient.

Patent and regulatory exclusivity may still affect a finished drug containing benzyl benzoate. Those rights belong to the finished-product sponsor or formulation developer. They do not prevent another company from manufacturing benzyl benzoate for unrelated products.

There is no conventional Paragraph IV risk for the excipient itself. Paragraph IV litigation can arise only when a generic drug applicant challenges a listed patent for a finished drug product in an ANDA. The presence of benzyl benzoate in that product does not create standalone Orange Book protection.

What is the Orange Book status of benzyl benzoate?

Benzyl benzoate is not an Orange Book-listed drug product merely because it is an excipient. The Orange Book identifies approved drug products and, where applicable, patents and exclusivity associated with those products. [4]

A sponsor evaluating a benzyl benzoate-containing product should distinguish:

• The excipient’s regulatory status.
• The finished product’s approval status.
• Any patents listed for the finished product.
• Any method-of-use or formulation claims.
• Any generic-drug litigation involving the finished product.

An ingredient-level Orange Book search is therefore insufficient for freedom-to-operate analysis. The product name, dosage form, route, sponsor, and approved labeling must be examined.

Which companies compete in benzyl benzoate supply?

The competitive field includes global chemical companies, Indian pharmaceutical-chemical manufacturers, Chinese producers, regional excipient suppliers, and distributors. Public information does not provide a consistent, audited market-share ranking for pharmaceutical-grade benzyl benzoate.

Competition is fragmented because the product is technically mature and relatively straightforward to manufacture. Supplier differentiation is strongest in the following areas:

• Consistent assay and impurity control.
• Pharmacopeial compliance.
• GMP documentation.
• DMF or regulatory-support capability.
• Reliable batch-to-batch color and odor profile.
• Low residual solvent and water content.
• Capacity for validated packaging.
• Multi-region supply and contingency inventory.
• Change-control discipline.

Large integrated chemical producers benefit from raw-material access and plant economics. Indian and Chinese producers often compete aggressively on price. European and North American suppliers can command a premium where customers value local inventory, regulatory support, and shorter audit cycles.

How strong is the benzyl benzoate supplier landscape?

The supplier landscape is commercially competitive but not completely interchangeable. The molecule itself has low technical complexity. Pharmaceutical qualification creates the main switching barrier.

A buyer may require:

• Supplier qualification and quality audit.
• Three or more validation batches.
• Compendial testing.
• Stability or compatibility data.
• Elemental impurity and residual-solvent assessments.
• Manufacturing-site change notification.
• Risk assessment for benzyl alcohol, benzoic acid, catalysts, and process impurities.
• Container-closure compatibility.
• Supply-chain mapping and business-continuity planning.

The result is a two-tier market. Technical and cosmetic material is highly price-sensitive. Pharmaceutical-grade material has greater retention and better margins because customers incur costs when changing suppliers.

Manufacturing and intellectual-property barriers

Manufacturing barriers are moderate rather than high. The process is established, raw materials are widely available, and the molecule does not require complex biotechnological production. The primary barriers are operational:

• Achieving consistent pharmaceutical quality.
• Managing odor and color specifications.
• Removing or controlling unreacted starting materials.
• Demonstrating low levels of process impurities.
• Maintaining validated cleaning and packaging systems.
• Supporting customer audits and regulatory filings.

Process patents may provide temporary protection for a particular route or purification method, but most competitive advantage is likely to come from manufacturing know-how, yield, plant utilization, quality systems, and customer qualification.

How do benzyl benzoate prices and margins behave?

Pricing is usually more sensitive to raw-material costs and plant utilization than to intellectual property. Key cost inputs include benzoic acid, benzyl alcohol, energy, packaging, labor, freight, and regulatory compliance.

Margin behavior differs by grade:

Grade	Price sensitivity	Margin potential	Main risk
Technical	Very high	Low	Overcapacity and substitution
Cosmetic	High	Low to medium	Buyer switching
Pharmaceutical oral/topical	Medium	Medium	Qualification and compliance costs
Pharmaceutical injectable	Lower	Medium to high	Validation and liability exposure
Specialty formulated	Lower	Higher	Small volumes and customer concentration

A supplier’s reported revenue can increase without corresponding volume growth if customers migrate toward higher-specification material, packaging, or documentation services. Conversely, a supplier can record volume growth with flat revenue during periods of chemical-cost deflation or aggressive tendering.

What is the financial trajectory for benzyl benzoate suppliers?

The likely financial trajectory is steady rather than explosive.

Near-term outlook

Near-term revenue should be supported by recurring demand from pharmaceuticals, cosmetics, fragrance, and veterinary products. Pharmaceutical demand is less volatile than fragrance or industrial demand, but it is unlikely to generate high double-digit growth for a mature excipient.

Profitability will depend on:

• Raw-material pass-through mechanisms.
• Utilization rates.
• Energy and freight costs.
• Regional production economics.
• Product mix between technical and pharmaceutical grades.
• Customer concentration.
• Regulatory remediation costs.

Medium-term outlook

Medium-term growth is likely to come from emerging-market pharmaceutical production, local manufacturing of dermatology products, and broader use of quality-assured excipients in regulated markets.

The strongest commercial opportunity is not the molecule itself. It is the upgraded supply package around the molecule:

• GMP production.
• Pharmacopeial certification.
• Regulatory filing support.
• Regional warehousing.
• Dual-source qualification.
• Injectable-grade controls.
• Long-term supply agreements.

Downside risks

The main downside risks are:

• Commodity-style price competition.
• Substitution by alternative solvents or vehicles.
• Customer backward integration.
• Demand concentration in a small number of topical or veterinary products.
• Regulatory restrictions on specific uses or routes.
• Supply disruption involving benzyl alcohol or benzoic acid.
• Product-quality events that trigger customer requalification.

What generic launch risks exist for benzyl benzoate-containing products?

Generic launch risk is product-specific. An ANDA applicant may face formulation-development and patent risks if the reference product contains benzyl benzoate in a protected dosage form or uses the compound in a patented delivery system.

The main generic risks are:

• Proving pharmaceutical equivalence.
• Matching viscosity, emulsion behavior, and release profile.
• Demonstrating acceptable local tolerance.
• Addressing residual-solvent and impurity controls.
• Avoiding listed formulation or method-of-use patents.
• Managing product-specific exclusivity.
• Establishing supply continuity for the excipient.

The excipient itself usually does not create the legal barrier. The formulation and finished-product patent estate do.

What licensing deals affect benzyl benzoate?

Publicly disclosed licensing deals focused specifically on benzyl benzoate as an excipient are uncommon. The compound is generally purchased through supply agreements, distribution arrangements, approved-vendor programs, and contract manufacturing relationships rather than licensed as proprietary technology.

Licensing can become relevant when benzyl benzoate is incorporated into:

• A patented long-acting injectable.
• A proprietary topical delivery system.
• A branded combination product.
• A controlled-release formulation.
• A platform technology involving a solvent or vehicle system.

In those situations, the commercial rights attach to the finished formulation or platform. They do not create exclusivity over ordinary benzyl benzoate production.

What geographic markets offer the strongest growth?

India and China are central to both supply and demand. India has a large generic-drug and excipient manufacturing base. China has broad chemical production capacity and a large domestic pharmaceutical market. Southeast Asia, Latin America, the Middle East, and Africa offer demand growth through increased access to topical medicines, veterinary products, and locally manufactured formulations.

North America and Western Europe remain attractive for premium pharmaceutical-grade sales because customers place greater value on documentation, audit readiness, and supply continuity. These markets are less likely to deliver rapid unit growth but can support better realized prices.

A geographically diversified supplier has an advantage when customers seek dual sourcing after disruptions in freight, energy, or chemical feedstocks.

What should investors and pharmaceutical buyers monitor?

The most useful indicators are:

• Benzyl alcohol and benzoic acid prices.
• Plant utilization and regional capacity.
• Pharmaceutical-grade versus technical-grade sales mix.
• FDA, EMA, and national regulatory observations.
• Customer qualification wins.
• New injectable or depot products.
• Changes in topical scabies-treatment demand.
• Freight and packaging costs.
• Supplier concentration by region.
• Product-quality recalls or impurity findings.
• Contract duration and pass-through clauses.

For investors, benzyl benzoate is more likely to be a portfolio and utilization product than a standalone growth engine. For pharmaceutical buyers, the critical issue is supplier reliability and regulatory quality rather than molecule-level IP.

Key Takeaways

• Benzyl benzoate is a mature pharmaceutical excipient and specialty chemical with no meaningful remaining molecule-level exclusivity.
• Pharmaceutical demand comes mainly from topical, dermatological, injectable, depot, veterinary, and generic formulations.
• The excipient market has no standalone Orange Book exclusivity and generally no Paragraph IV exposure.
• Formulation, delivery-system, manufacturing-process, and method-of-use patents can affect finished products containing benzyl benzoate.
• Supplier competition is broad, with India and China important to global capacity and North America and Europe important to premium regulated-market demand.
• Financial growth should be modest and volume-led, with better margins for pharmaceutical-grade and injectable-grade material.
• The strongest supplier advantages are GMP compliance, compendial quality, regulatory support, validated supply, and regional inventory.
• Pricing power is limited because the chemistry is mature and alternative suppliers are available.
• The key commercial risk is commodity-style competition. The key technical risk is failure to meet route-specific pharmaceutical specifications.
• Licensing and litigation generally concern finished formulations rather than benzyl benzoate as a standalone excipient.

FAQs

Is benzyl benzoate an active pharmaceutical ingredient or an excipient?

It can be either, depending on the product and jurisdiction. In many formulations it is an excipient, solvent, or vehicle. In some antiparasitic products it is used as an active ingredient.

Can benzyl benzoate be used in injectable drugs?

It can be used in selected injectable or depot formulations, but suitability depends on route, concentration, impurity profile, sterility controls, toxicology, and regulatory precedent.

Is pharmaceutical-grade benzyl benzoate interchangeable between suppliers?

Not automatically. The chemical identity may be equivalent, but supplier changes can require qualification, comparability testing, stability assessment, and regulatory notification.

Does benzyl benzoate have a Drug Master File?

A supplier may maintain a Drug Master File or comparable regulatory package, but DMF availability is supplier-specific. A DMF does not create patent exclusivity and does not replace finished-product sponsor responsibility.

Can benzyl benzoate be replaced by another excipient?

Potentially, but replacement depends on the formulation’s solvency, viscosity, partitioning, toxicity, route, release profile, container compatibility, and regulatory history. A substitute may require meaningful reformulation and new stability work.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. European Medicines Agency. (2011). Guideline on excipients in the label and package leaflet of medicinal products for human use. https://www.ema.europa.eu/

3. United States Pharmacopeia. (2024). Benzyl benzoate. In United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files